Page 40 - 2019_04-Haematologica-web

D.P. McLornan et al.
40. Gupta V, Kosiorek HE, Mead A, Klisovic RB,
et al. Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: myeloproliferative disorders research Consortium 114 study. Biol Blood Marrow Transplant. 2019;25(2):256-264.
41. Robin M, Francois S, Huynh A, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the SFGMTC. Blood, 2013;122(21):306.
42. Shanavas M, Popat U, Michaelis LC, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibro- sis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant. 2016;22(3):432-440.
43. Shahnaz Syed Abd Kadir S, Christopeit M, Gerald W, et al. Impact of ruxolitinib pre- treatment on outcomes after allogeneic stem cell transplantation in patients with myelofi- brosis. Eur J Haematol. 2018;101(3):305-317.
44. Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, et al. Peritransplantation ruxoli- tinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(10): 2152-2156.
45. Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft- versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062-2068.
46. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as cura- tive therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355-365.
47. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633.
48. Robin M, Porcher R, Wolschke C, et al. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing Transplantation for Myelofibrosis. Biol Blood Marrow Transplant. 2016;22(7):1206-1211.
49. Rondelli D, Goldberg JD, Isola L, et al. MPD- RC 101 prospective study of reduced-intensi- ty allogeneic hematopoietic stem cell trans- plantation in patients with myelofibrosis. Blood. 2014;124(7):1183-1191.
50. Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell trans- plantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514–1522.
51. Robin M, Chevret S, Koster L, et al. In vivo T cell depletion in patients with myelofibrosis transplanted from an HLA-matched sibling donor: an EBMT study. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session: Bone Marrow Transplant. 2018 Abstract supplements.
52. Raj K, Eikema DJ, McLornan DP, et al. Family mismatched allogeneic stem cell transplanta-
tion for myelofibrosis: report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018 Nov5. [Epub ahead of print]
53. Takagi S, Ota Y, Uchida N, et al. Successful engraftment after reduced intensity umbilical cord blood transplantation for myelofibrosis. Blood. 2010;116(4):649–652.
54. Robin M, Giannotti F, Deconinck E, et al. Unrelated cord blood transplantation for patients with primary or secondary myelofi- brosis. Biol Blood Marrow Transplant. 2014;20(11):1841-1846.
55. Tefferi A, Mudireddy M, Mannelli F, et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018; 32(5):1200-1210.
56. Alchalby H, Zabelina T, Stübig T, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(2): 279-281.
57. Cahu X, Chevallier P, Clavert A, et al. Allo- SCT for Philadelphia-negative myeloprolifer- ative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2014;49(6):756-760.
58. Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW. No influence of V617F mutation in JAK2 on out- come after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibro- sis. Biol Blood Marrow Transplant. 2006;12(12):1350–1351.
59. Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood. 2010;116(18):3572–3581.
60. Panagiota V, Thol F, Markus B, et al. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia. 2014;28(7):1552-1555.
61. Kröger N, Panagiota V, Badbaran A, et al. Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(7):1095-1101.
62. Alchalby H, Yunus DR, Zabelina T, Ayuk F, Kröger N. Incidence and risk factors of poor graft function after allogeneic stem cell trans- plantation for myelofibrosis. Bone Marrow Transplant. 2016;51(9):1223-1227.
63. Hart C, Klatt S, Barop J, et al. Splenic pool- ing and loss of VCAM-1 causes an engraft- ment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Haematologica 2016;101 (11):1407-1416.
64. Alchalby H, Badbaran A, Bock O, et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic- SCT. Bone Marrow Transplant. 2010;45(9): 1404–1407
65. Rumi E, Passamonti F, Arcaini L, et al. Molecular remission after allo-SCT in a patient with post-essential thrombo-
cythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplant. 2010;45(4):798–800.
66. Wolschke C, Badbaran A, Zabelina T, et al. Impact of molecular residual disease post allografting in myelofibrosis patients. Bone Marrow Transplant. 2017;52(11):1526-1529.
67. Kroger N, Alchalby H, Klyuchnikov E, et al. JAK2-V617F- triggered pre-emptive and sal- vage adoptive immunotherapy with donor- lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009;113(8):1866– 1868.
68. McLornan DP, Szydlo R, Robin M, et al. Outcome of patients with myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. Br J Haematol. 2018 May 29. [Epub ahead of print]
69. Janson D, Ayuk F. A, Wolschke C, et al. Ruxolitinib for myelofibrosis patients relaps- ing after allogeneic hematopoietic transplan- tation. Blood. 2016;128(22):1948.
70. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: signifi- cant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120(20):4168-4171.
71. Tefferi A, Finke CM, Lasho TL et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and throm- bocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014;28(2):431-433.
72. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477.
73. Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic corre- lates among 155 patients. Leukemia. 2012;26(5):1135-1137.
74. Tefferi A, Lasho TL, Finke C, et al. Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. Leukemia. 2018;2(3):837-839.
75. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor sur- vival in myelofibrosis. Blood. 2011;118(19): 5227-5234.
76. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened sur- vival: clinical evidence for leukemogenic col- laboration with JAK2V617F. Leukemia. 2012;26(3):475-480.
77. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell trans- plantation for patients with primary myelofi- brosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014;20(1):89-97.
78. Jain T, Kunze KL, Temkit M, et al. Comparison of reduced intensity condition- ing regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019;54(2):204-211.
668
haematologica | 2019; 104(4)